Brief: Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss
18/10/2023 12:39
Oct 18 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN ANNOUNCES POSITIVE PRECLINICAL DATA SHOWING
SYNERGISTIC
WEIGHT LOSS; INITIATING CLINICAL STUDY OF MELANOCORTIN 4
RECEPTOR AGONIST + GLP-1 IN OBESE PATIENTS
* PALATIN TECHNOLOGIES INC - GLP-1 & MC4R AGONIST
CO-ADMINISTRATION DATA SHOWS INCREASED WEIGHT LOSS AND GREATER
GLUCOSE CONTROL ABOVE MONOTHERAPY
* PALATIN TECHNOLOGIES INC - CLINICAL STUDY CURRENTLY
EXPECTED TO
START 1Q CALENDAR YEAR 2024
* PALATIN TECHNOLOGIES INC - CLINICAL STUDY CURRENTLY
EXPECTED TO
START 1Q CALENDAR YEAR 2024
Source text for Eikon: ID:nPn1QCmJya
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity